TRDA Earnings Date: Nov 5, 2026 (Estimated) — Entrada Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is TRDA's next earnings date?
Entrada Therapeutics, Inc. (TRDA) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 7:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.98 on revenue of $2.1M.
How did TRDA do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), Entrada Therapeutics, Inc. posted EPS of -$1.01 versus the -$1.05 estimate, a beat of 5.6%. Revenue was $898,000 against a $2.2M estimate. The stock's 1-day post-earnings move was -2.5%.
How much does TRDA stock move after earnings?
TRDA beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 4.0% (up or down) in the day after earnings.
About Entrada Therapeutics, Inc.
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | -1.05 | -1.01 | +5.61% | $898,000 | ✅ Beat | -2.49% | -2.76% | +0.83% |
| 2026-05-19 | Q1 2026 | -1.03 | -0.95 | +7.77% | $875,000 | ✅ Beat | -4.07% | +13.75% | +15.62% |
| 2026-02-26 | Q4 2025 | -1.22 | -0.94 | +22.95% | $1.3M | ✅ Beat | +6.76% | +4.34% | +2.75% |
| 2025-11-06 | Q3 2025 | -0.99 | -1.06 | -7.07% | $1.6M | ❌ Miss | +0.14% | +15.42% | +48.70% |
| 2025-08-06 | Q2 2025 | -0.86 | -1.04 | -20.93% | $1.9M | ❌ Miss | +2.06% | -11.49% | -10.46% |
| 2025-02-27 | Q4 2024 | -0.66 | 0.03 | +104.55% | $37.4M | ✅ Beat | -0.33% | -11.98% | -17.14% |
| 2024-11-05 | Q3 2024 | -0.73 | -0.35 | +52.05% | $19.6M | ✅ Beat | +4.78% | +11.93% | +12.32% |
| 2024-08-13 | Q2 2024 | 0.14 | 1.55 | +1007.14% | $94.7M | ✅ Beat | +11.26% | +16.26% | +4.57% |
Showing last 8 quarters.